RPTR-147:1

News alerts, weekly reports and conference planners

Company:

Repertoire

Drug class:

T-cell stimulant, IL-15R stimulant

Related drugs:

‹

›

over3years

[VIRTUAL] Tracking and decoding the antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME IL-15 (RPTR-147) (AACR 2021)

Antigen specific T cell reactivities and clonotypes were identified in the peripheral repertoire. We confirmed that T cells were successfully expanded against TAAs and that these T cells do infiltrate the tumors as evidenced by bulk TCR sequencing of post-treatment tumor biopsies.

over 3 years ago

Clinical • Late-breaking abstract • IO biomarker

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • WT1 (WT1 Transcription Factor) • BIRC5 (Baculoviral IAP repeat containing 5) • CD4 (CD4 Molecule) • PRAME (Preferentially Expressed Antigen In Melanoma)

RPTR-147:1

4years

[VIRTUAL] PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients (SITC 2020)

Dose-escalation is proceeding. Ongoing biomarker analysis will inform future clinical strategies in matching patients to an optimized PRIME IL-15 T cell product.

4 years ago

Clinical • P1 data • Late-breaking abstract • IO biomarker

CD8 (cluster of differentiation 8) • BIRC5 (Baculoviral IAP repeat containing 5) • PRAME (Preferentially Expressed Antigen In Melanoma)

RPTR-147:1

4years

Dose-escalation is proceeding. Ongoing biomarker analysis will inform future clinical strategies in matching patients to an optimized PRIME IL-15 T cell product.

4 years ago

Clinical • P1 data • Late-breaking abstract • IO biomarker

CD8 (cluster of differentiation 8) • BIRC5 (Baculoviral IAP repeat containing 5) • PRAME (Preferentially Expressed Antigen In Melanoma)

RPTR-147:1